On November 16, 2022 Scandion Oncology (Scandion) reported its interim report for Q3 2022 (Press release, Scandion Oncology, NOV 16, 2022, View Source;interim-report-q3-2022,c3667570 [SID1234624141]). The following is taken from the report.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Johnny Stilou, Acting CEO & CFO, comments
"In the third quarter of 2022 we managed to raise approximately 42 MDKK net in a very difficult stock market. The raised capital will take us well into 2024."
Shares outstanding, ending
Highlights during Q3 2022
On July 4, Scandion announced final outcome of its rights issue. Through the issue, Scandion raises approximately SEK 75 million before deduction of issue related costs.
On July 26, Scandion’s rights issue was registered with the Danish Business Authority.
On August 17, Scandion announced extension of the PANTAX trial due to better-than-expected tolerability of SCO-101.
On August 19, Scandion received approvals for next parts of the CORIST trial. The development of SCO-101 will continue as planned with expansion of the CORIST trial expected to commence during the third quarter of 2022.
On August 31, Scandion announced changes to Executive Management.
On September 31, Scandion announced topline results from part 2 of the CORIST phase II trial. Data from part 2 of the trial confirm the safety and tolerability of SCO-101. The trial will continue with part 3 exploring an optimized dosing schedule, aiming to utilize the full potential of SCO-101 in this indication and combination.
Highlights after the end of the period
On October 10, Scandion initiates recruitment in part 3 of the CORIST phase II trial.
On October 28, Scandion announce results of extraordinary general meeting.
The interim report Q3 2022 is available on the Company’s website: www.scandiononcology.com.
Audiocast today, November 16 at 10:00 am CET
Today at 10:00, Scandion Oncology’s executive management will host a webcast and conference call presenting the results and a company update.
At the end of the presentation there will be a Q&A session.
The information was provided by the contact person above for publication on November 16, 2022, at 08.30 CET.